Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAREON-Lung-1: Obrixtamig + Atezolizumab, Carboplatin, and Etoposide in ES-SCLC
NCT07472517Phase 3Recruiting
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2026
- Primary completion
- Sep 2028
- Countries
- 42
01
Overview
A Phase 3 trial of obrixtamig in small cell lung cancer (SCLC), sponsored by Boehringer Ingelheim. Started Apr 2026; status: recruiting.
02
Drugs
obrixtamig
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT07472517.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07472517.